Ron Piervincenzi Named Next CEO of USP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ron Piervincenzi Named Next CEO of USP


The Board of Trustees of the United States Pharmacopeial Convention (USP) today announced that Ron Piervincenzi will become the chief executive officer of USP and chair of USP’s standards-setting body, the Council of Experts. Piervincenzi will assume these responsibilities Feb. 1, 2014.

“I am excited and honored to lead USP’s mission to improve global health,” said Piervincenzi. “This is an outstanding organization doing life-changing work around the world, and I look forward to focusing the collective energy, expertise and knowledge of USP’s global volunteers and staff on the challenges of the future.”

“In Dr. Piervincenzi we have found an outstanding new leader for USP, which has seen unprecedented growth over the past several years,” said USP Board of Trustees Chair, Thomas R. Temple, R.Ph., M.S. “I am excited about Dr. Piervincenzi’s commitment to the next phase of USP’s unique mission to develop and promote cutting edge global standards for pharmaceuticals, food, and dietary supplements.”

Piervincenzi was a partner and leader in McKinsey & Company's Global Pharmaceutical and Medical Products Practice for 12 years where, among other responsibilities, he launched McKinsey's global drug safety, medical and regulatory service line.  Dr. Piervincenzi earned an MS and PhD from Duke University in Biomedical Engineering with research focused on protein engineering.

Source: US Pharmacopeial Convention (USP)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here